As of May 22
| +0.14 / +1.51%|
The 1 analysts offering 12-month price forecasts for SciClone Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median estimate represents a -15.25% decrease from the last price of 9.44.
The current consensus among 1 polled investment analysts is to Hold stock in SciClone Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.